Project
Abbvie M15-572 Phase 3 PsA mit inadäquater Response auf bDMARD
Automatically Closed · 2017 until 2024
Bartz-Batliner Mira, Hutz Carina Liane, Rubbert-Roth Andrea, Neumann Thomas
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Automatically Closed
Start Date
2017
End Date
2024
Financing
Industry
Keywords
Psoriasis, Arthritis, humira
Brief description/objective
A Phase 3, Randomized, Double-Blind, Study
Comparing Upadacitinib (ABT-494) to Placebo and to
Adalimumab in Subjects with Active Psoriatic
Arthritis Who Have a History of Inadequate
Response to at Least One Non-Biologic Disease
Modifying Anti-Rheumatic Drug (DMARD) – SELECT –
PsA 1